

Special Issue

Drug Delivery Systems for Asthma and Pulmonary Diseases, 2nd Edition

Message from the Guest Editors

For decades, asthmatics have relied on nebulization and aerosols for delivery, but advances in polymerization and nucleic acid packaging have shown promise in the potential of lasting relief being provided by targeted therapies for the epithelial cells involved in asthmatic exacerbations. Other respiratory pathologies (including COVID-19) are benefiting or could also benefit from advanced inhalative therapies. Additionally, the liposomal delivery of therapeutics could increase the local and systemic bioavailability of active ingredients while reducing the effects of first-pass metabolism. Of particular interest is the packaging potential of biopolymers in delivering new therapies derived from monoclonal antibodies, as well as gel- or film-based applications for use in the lungs. We invite you to submit perspectives and research on the packaging of asthmatic medications and of drugs targeting other respiratory pathologies, on increases in delivery efficiency, and on the biochemical interactions between target cells and engineered delivery systems

Guest Editors

Prof. Dr. Jesus Perez-Gil

Department of Biochemistry, Faculty of Biology, Universidad Complutense, 28040 Madrid, Spain

Dr. Bryan Mathis

International Medical Center, University of Tsukuba Affiliated Hospital, Tsukuba 305-8576, Japan

Deadline for manuscript submissions

closed (20 December 2024)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/192563

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).